RPS17A Antibody

What is RPS17 and why is it important in research?

RPS17 (ribosomal protein S17) is a component of the small ribosomal subunit, which is part of the larger ribonucleoprotein complex responsible for protein synthesis in cells. In humans, the canonical RPS17 protein consists of 135 amino acid residues with a molecular mass of approximately 15.6 kDa, and it demonstrates subcellular localization in both the nucleus and cytoplasm . The protein is widely expressed across various tissue types and belongs to the Eukaryotic ribosomal protein eS17 family, playing a crucial role in ribosomal assembly and function . RPS17's significance in research stems from its fundamental role in protein synthesis and its association with Diamond-Blackfan anemia, making it an important target for studies focused on ribosomal biology, protein synthesis disorders, and certain congenital diseases . Orthologs of RPS17 have been identified in multiple species including mouse, rat, bovine, frog, chimpanzee, and chicken, highlighting its evolutionary conservation and functional importance .

What are the common applications for RPS17 antibodies in research?

RPS17 antibodies are versatile tools employed in multiple immunodetection methods across various research contexts. Western Blot (WB) is the most widely utilized application, with recommended dilutions typically ranging from 1:500 to 1:2000, allowing researchers to detect and quantify RPS17 protein in complex biological samples . Immunohistochemistry (IHC) represents another valuable application, with dilutions generally between 1:50 and 1:500, enabling visualization of RPS17 within tissue sections and providing insights into its spatial distribution in physiological and pathological contexts . Immunofluorescence (IF) and immunocytochemistry (ICC), with recommended dilutions of 1:200 to 1:800, allow for high-resolution subcellular localization studies of RPS17 in cultured cells . Additionally, enzyme-linked immunosorbent assay (ELISA) serves as a quantitative method for measuring RPS17 levels in biological fluids and cell lysates . For optimal results across these applications, researchers should titrate antibody concentrations based on their specific experimental systems, as detection sensitivity can vary depending on the sample type and preparation method .

What are the key considerations when selecting an RPS17 antibody?

When selecting an RPS17 antibody, researchers should evaluate several critical parameters to ensure experimental success and reliable results. First, consider the antibody's validated reactivity with species of interest—commercially available RPS17 antibodies demonstrate reactivity with human and mouse samples, with some extending to rat, bovine, and other species . The antibody class (polyclonal versus monoclonal) represents another important consideration; polyclonal antibodies like the commonly available rabbit anti-RPS17 antibodies offer broader epitope recognition but potentially greater batch-to-batch variability compared to monoclonals . Researchers should carefully examine the immunogen information to understand which region of RPS17 the antibody targets, as this affects specificity and application suitability . The validated applications (WB, IHC, IF/ICC, ELISA) must align with the intended experimental use, and researchers should prioritize antibodies with demonstrated success in their application of interest . Finally, review any available validation data including Western blot images showing the expected molecular weight (approximately 16 kDa), positive controls in relevant cell lines (such as HEK-293, HeLa, Jurkat, and PC-3 cells), and cross-reactivity information to ensure specific target binding .

How should RPS17 antibodies be stored and handled?

Proper storage and handling of RPS17 antibodies are essential for maintaining their functionality and extending their useful lifespan. RPS17 antibodies are typically supplied in liquid form containing a storage buffer of PBS with 0.02% sodium azide and 50% glycerol at pH 7.3, which helps preserve antibody stability during storage . These antibodies should be stored at -20°C, where they generally remain stable for one year after shipment when maintained under appropriate conditions . Importantly, aliquoting is typically unnecessary for -20°C storage of these antibodies, reducing the risk of contamination or degradation associated with repeated freeze-thaw cycles . When handling the antibodies, researchers should note that some preparations (particularly those in 20μl sizes) may contain 0.1% BSA as a stabilizer, which should be considered when designing experiments where BSA might interfere . Before use, allow the antibody to equilibrate to room temperature and gently mix by inversion or light vortexing to ensure homogeneity without causing protein denaturation or aggregation . Always wear appropriate personal protective equipment when handling these reagents, as some contain sodium azide, which is toxic and requires proper disposal procedures .

How should I optimize Western blot conditions for RPS17 antibody detection?

Optimizing Western blot conditions for RPS17 antibody detection requires systematic adjustment of multiple parameters to achieve specific and sensitive detection. Begin by preparing protein samples from validated positive control cell lines such as HEK-293, HeLa, Jurkat, PC-3, or NIH/3T3 cells, ensuring complete protein extraction and denaturation . Given RPS17's relatively small size (16 kDa), select an appropriate gel percentage (12-15% acrylamide) to achieve optimal protein resolution in the lower molecular weight range . When transferring proteins, consider using PVDF membranes and optimize transfer conditions (lower voltage for longer duration) to ensure efficient transfer of small proteins without over-transfer . For antibody incubation, start with a mid-range dilution (1:1000) from the recommended range (1:500-1:2000) and adjust based on signal strength and background levels in preliminary experiments . Incorporate proper controls including positive control lysates, negative controls (non-expressing samples or knockdown cells if available), and loading controls appropriate for ribosomal proteins . If non-specific bands appear, optimize blocking conditions (consider 5% BSA instead of milk for phospho-specific antibodies) and increase washing stringency between antibody incubations . Finally, adjust exposure times during detection to capture the specific 16 kDa band without saturation, which is essential for accurate quantification .

What are the critical considerations for immunohistochemistry with RPS17 antibodies?

Successful immunohistochemistry with RPS17 antibodies requires attention to several critical factors affecting sensitivity and specificity. Antigen retrieval represents a crucial step, with RPS17 antibodies typically requiring heat-induced epitope retrieval using TE buffer at pH 9.0, although citrate buffer at pH 6.0 serves as an alternative option when TE buffer yields suboptimal results . When examining mouse tissue, cerebellum has been validated as a positive control tissue, providing a reliable reference for establishing staining protocols . The antibody dilution requires careful optimization, with recommended ranges of 1:50 to 1:500; researchers should begin with a middle dilution and adjust based on signal intensity and background levels . Include both positive controls (tissues known to express RPS17) and negative controls (either no primary antibody or isotype controls) in each experimental run to validate staining specificity . Given RPS17's expression in both nucleus and cytoplasm, evaluate staining patterns carefully, confirming subcellular localization is consistent with expected distribution . Detection system selection deserves consideration, with polymer-based systems often providing better sensitivity and reduced background compared to traditional avidin-biotin methods for ribosomal proteins . Finally, counterstaining intensity should be optimized to provide cellular context without obscuring specific RPS17 immunoreactivity, and mounting media selection should preserve long-term fluorescence if using fluorescent detection methods .

How can I optimize immunofluorescence protocols for RPS17 detection?

Optimizing immunofluorescence (IF) protocols for RPS17 detection requires careful attention to fixation, permeabilization, and antibody incubation conditions. Begin with validated cell lines such as U2OS cells, which have demonstrated positive staining with RPS17 antibodies in previous studies . The fixation method significantly impacts epitope accessibility and retention; while 4% paraformaldehyde (PFA) provides good structural preservation, methanol fixation may better expose certain epitopes in ribosomal proteins—conducting parallel experiments with both fixatives can identify optimal conditions . Permeabilization requires careful optimization, as excessive permeabilization may damage cellular structures while insufficient permeabilization limits antibody access; start with 0.1-0.2% Triton X-100 for PFA-fixed cells or skip this step for methanol-fixed cells . Antibody dilution should begin in the middle of the recommended range (1:200-1:800) and adjust based on signal-to-noise ratio in preliminary experiments . Given RPS17's abundant expression in both nucleus and cytoplasm, confocal microscopy may provide superior resolution of subcellular localization compared to standard epifluorescence microscopy . Include appropriate controls such as primary antibody omission, isotype controls, and when possible, RPS17 knockdown or knockout samples to validate staining specificity . Finally, when performing co-localization studies with other ribosomal or nucleolar markers, carefully select fluorophores with minimal spectral overlap and include single-stained controls for accurate compensation during image acquisition and analysis .

What sample preparation methods are recommended for detection of RPS17 in different cell types?

Sample preparation methods for RPS17 detection must be tailored to cell type and experimental goals to ensure optimal results. For adherent cell lines such as HEK-293, HeLa, PC-3, NIH/3T3, and U2OS, direct lysis on the culture plate using RIPA buffer supplemented with protease inhibitors efficiently extracts RPS17 while minimizing protein degradation . Suspension cells like Jurkat require pelleting before lysis, with gentle processing to preserve cellular architecture for downstream applications . When preparing samples for Western blot analysis, complete protein denaturation is essential; heat samples at 95°C for 5 minutes in Laemmli buffer containing SDS and a reducing agent to ensure proper migration of this 16 kDa protein . For tissues, particularly mouse cerebellum which serves as a validated positive control, cryosectioning followed by fixation often provides better epitope preservation compared to formalin-fixed paraffin-embedded (FFPE) processing, though FFPE sections can yield good results with appropriate antigen retrieval . When preparing cells for immunofluorescence, growing cultures on coated coverslips improves adherence and morphology, while maintaining appropriate cell density prevents excessive overlapping that could complicate imaging analysis . For all applications, freshly prepared samples generally yield superior results, though flash-frozen samples stored at -80°C maintain antigenicity for extended periods . Finally, when analyzing RPS17 in subcellular fractions, differential centrifugation protocols separating nuclear and cytoplasmic compartments can provide valuable insights into the protein's distribution across these compartments in different physiological or experimental conditions .

What are common issues when detecting RPS17 by Western blot and how can they be resolved?

Western blot detection of RPS17 can present several technical challenges requiring specific troubleshooting approaches. The most common issue involves detecting multiple bands instead of the expected single 16 kDa band, which may result from protein degradation, non-specific antibody binding, or detection of RPS17 isoforms . To address this, researchers should ensure sample freshness, add protease inhibitors during lysis, optimize antibody concentration, increase washing stringency, and consider alternative blocking agents (BSA instead of milk) . Another frequent challenge is weak or absent signal despite confirmed RPS17 expression in the sample; this may occur due to insufficient protein loading, inefficient protein transfer (especially common with small proteins like RPS17), or antibody degradation . Solutions include increasing protein concentration, optimizing transfer conditions for small proteins (using PVDF membranes and adding 10-20% methanol to transfer buffer), and testing antibody functionality with verified positive controls . High background signal represents another common obstacle, typically resulting from insufficient blocking, excessive primary or secondary antibody concentration, or inadequate washing . Researchers can overcome this by extending blocking time, diluting antibodies further, increasing wash duration and frequency, and ensuring high-quality reagents throughout the protocol . Finally, inconsistent results between experiments often stem from variable sample preparation or handling; implementing standardized protocols for sample collection, storage, and processing while maintaining consistent experimental conditions across replicates will significantly improve reproducibility .

How can I differentiate between specific and non-specific staining in immunohistochemistry using RPS17 antibodies?

Differentiating between specific and non-specific staining in immunohistochemistry using RPS17 antibodies requires implementing rigorous controls and analytical approaches. First, always include appropriate negative controls: sections incubated with isotype-matched control antibodies instead of RPS17 antibody, and sections processed with secondary antibody only (primary antibody omission control) . Positive controls are equally essential, with mouse cerebellum tissue serving as a validated positive control for RPS17 staining; consistent staining patterns in these controls across experiments helps confirm specificity . Evaluate staining patterns carefully—RPS17 demonstrates both nuclear and cytoplasmic localization, so staining should be consistent with this expected subcellular distribution rather than showing unusual localization patterns . Titrate antibody concentration systematically; specific staining typically exhibits a dose-dependent relationship with antibody concentration, while non-specific background may remain relatively constant or increase disproportionately at higher concentrations . Peptide competition assays provide another powerful verification method, where pre-incubation of the antibody with the immunizing peptide should abolish or significantly reduce specific staining without affecting non-specific background . Compare staining patterns across multiple antibodies targeting different epitopes of RPS17 when possible; concordant results from independent antibodies strongly support staining specificity . Finally, correlate immunohistochemical findings with orthogonal techniques such as in situ hybridization for RPS17 mRNA or Western blot analysis of the same tissue types to provide multi-technique validation of protein expression patterns .

What factors might affect the detection sensitivity of RPS17 in experimental samples?

Multiple factors can significantly influence the detection sensitivity of RPS17 in experimental samples, requiring careful consideration during experimental design and execution. Sample preparation methods fundamentally impact sensitivity; fresh samples typically yield superior results compared to stored samples, while proper extraction buffers (RIPA or NP-40 based buffers with protease inhibitors) ensure optimal protein preservation . Fixation conditions dramatically affect epitope accessibility in immunohistochemistry and immunofluorescence applications, with overfixation potentially masking epitopes and underfixation risking structural preservation; optimization of fixation duration and conditions for each sample type is therefore critical . Antigen retrieval methods significantly influence epitope exposure in fixed tissues, with RPS17 antibodies showing optimal results using TE buffer at pH 9.0, though some applications may benefit from citrate buffer at pH 6.0 as an alternative . Antibody quality and batch variation can introduce inconsistency, particularly with polyclonal antibodies; maintaining records of antibody lot numbers and performing validation with each new lot helps mitigate this variability . Detection system selection substantially impacts sensitivity thresholds, with signal amplification methods (such as tyramide signal amplification) potentially enhancing detection of low-abundance targets compared to conventional systems . Expression levels of RPS17 vary across tissue types and cellular states, necessitating adjustment of detection protocols based on expected abundance . Finally, the presence of post-translational modifications or protein-protein interactions might mask epitopes in certain cellular contexts, potentially requiring denaturation steps or alternative antibodies targeting different epitopes to achieve consistent detection .

How can I verify the specificity of my RPS17 antibody in research applications?

Verifying antibody specificity is crucial for generating reliable and reproducible data with RPS17 antibodies across all applications. Begin with Western blot analysis to confirm that the antibody detects a single band at the expected molecular weight of 16 kDa in positive control samples such as HEK-293, HeLa, Jurkat, PC-3, or NIH/3T3 cell lysates . Employ genetic approaches by comparing staining patterns in wild-type cells versus RPS17 knockdown (siRNA) or knockout (CRISPR/Cas9) cells; specific antibodies should show significantly reduced or absent signal in cells with depleted RPS17 . Peptide competition assays provide another powerful verification method, where pre-incubating the antibody with excess immunizing peptide should abolish or substantially reduce specific binding in all applications . Orthogonal technique correlation strengthens validation—confirm that protein expression patterns detected by the antibody correlate with mRNA expression data from RT-PCR or RNA sequencing of the same samples . Cross-species reactivity testing can leverage evolutionary conservation; if RPS17 is highly conserved across species, the antibody should detect the protein in multiple species with similar specificity, though some species-specific variations may exist . Multiple antibody concordance offers additional validation—using independent antibodies targeting different epitopes of RPS17 should yield similar detection patterns if each is specific . Finally, mass spectrometry-based confirmation represents the gold standard; immunoprecipitation with the RPS17 antibody followed by mass spectrometry analysis should identify RPS17 as the predominant precipitated protein, providing definitive evidence of antibody specificity .

How can RPS17 antibodies be used to study ribosome biogenesis and function?

RPS17 antibodies offer powerful tools for investigating ribosome biogenesis and function through multiple sophisticated experimental approaches. Researchers can employ immunoprecipitation (IP) with RPS17 antibodies followed by mass spectrometry to identify protein interaction partners involved in ribosome assembly, potentially uncovering novel regulatory mechanisms or assembly factors in different cellular contexts . Chromatin immunoprecipitation (ChIP) assays utilizing these antibodies enable investigation of interactions between RPS17 and ribosomal DNA, providing insights into the regulation of ribosomal RNA transcription and early assembly events . For dynamic studies, combining RPS17 immunofluorescence with pulse-chase labeling of newly synthesized RNA allows visualization of ribosome assembly kinetics and trafficking through nuclear and cytoplasmic compartments . Researchers can implement proximity ligation assays (PLA) with antibodies against RPS17 and other ribosomal proteins or assembly factors to visualize and quantify specific protein-protein interactions within intact cells at endogenous expression levels . Sucrose gradient fractionation followed by Western blot detection of RPS17 enables tracking of small ribosomal subunit assembly intermediates, mature 40S subunits, and actively translating ribosomes, providing a comprehensive view of ribosome maturation stages . For tissue-specific studies, immunohistochemistry with RPS17 antibodies can reveal differential expression patterns across development or in disease states, potentially highlighting tissues with altered ribosome biogenesis . Finally, combining RPS17 antibodies with nascent protein labeling techniques such as puromycin incorporation allows correlation between ribosome localization and active translation sites within cells .

What role does RPS17 play in Diamond-Blackfan anemia and how can antibodies help in studying this connection?

Diamond-Blackfan anemia (DBA) represents a rare congenital erythroid aplasia associated with mutations in several ribosomal protein genes, including RPS17, with antibody-based approaches providing crucial insights into disease mechanisms . RPS17 antibodies enable comparative protein expression analysis between healthy controls and DBA patient samples, revealing potential differences in expression levels, subcellular localization, or post-translational modifications that might contribute to disease pathogenesis . Researchers can employ immunohistochemistry with RPS17 antibodies on bone marrow biopsies to evaluate erythroid progenitor populations in DBA patients with RPS17 mutations, potentially revealing cell-specific alterations in protein expression or localization . Co-immunoprecipitation studies using RPS17 antibodies allow investigation of how disease-associated mutations affect interactions with other ribosomal proteins or assembly factors, potentially disrupting critical protein complexes required for normal erythropoiesis . For functional studies, researchers can combine RPS17 antibodies with polysome profiling to assess how mutations impact ribosome assembly and translation efficiency in patient-derived cells, connecting molecular defects to disease phenotypes . Immunofluorescence approaches permit visualization of nucleolar stress responses in cells expressing mutant RPS17, as ribosomal protein mutations often trigger p53 activation through nucleolar disruption . Western blot analysis with phospho-specific antibodies against p53 and its targets, alongside RPS17 detection, enables quantification of stress response pathway activation in various cellular models of DBA . Finally, these antibodies can support translational research by helping evaluate the efficacy of therapeutic approaches aimed at correcting ribosomal defects or modulating resulting stress responses in preclinical DBA models .

How can RPS17 antibodies be used in co-immunoprecipitation studies to identify protein interaction partners?

Co-immunoprecipitation (co-IP) with RPS17 antibodies represents a powerful approach for identifying protein interaction partners within the ribosomal assembly pathway and translation machinery. When designing co-IP experiments, researchers should select lysis buffers carefully—NP-40 or Triton X-100 based buffers (0.5-1%) with physiological salt concentrations (150mM NaCl) typically preserve protein-protein interactions while effectively solubilizing membrane-associated ribosomes . Pre-clearing lysates with protein A/G beads before adding the RPS17 antibody removes proteins that bind non-specifically to beads or immunoglobulins, significantly reducing background . For antibody selection, validated antibodies that recognize native (non-denatured) RPS17 are essential; most commercial RPS17 antibodies are polyclonal and suitable for immunoprecipitation, though batch testing is recommended . To enhance specificity, researchers can perform parallel immunoprecipitations with pre-immune serum or isotype-matched control antibodies as negative controls to identify non-specific binding proteins . Cross-linking strategies (using DSP, formaldehyde, or other reversible cross-linkers) can stabilize transient interactions that might otherwise be lost during purification, particularly valuable for capturing dynamic assembly intermediates . For detecting low-abundance interaction partners, scaling up input material and implementing sensitive detection methods such as silver staining or mass spectrometry increases discovery potential . When analyzing results, focus on proteins uniquely present in RPS17 immunoprecipitates but absent in control samples, while considering both stoichiometric and substoichiometric interactors that may represent regulatory factors . Finally, validate key interactions through reciprocal co-IPs, proximity ligation assays, or fluorescence resonance energy transfer (FRET) to confirm biological relevance .

What approaches can be used to study post-translational modifications of RPS17 using specific antibodies?

Studying post-translational modifications (PTMs) of RPS17 requires specialized antibody-based approaches to detect and characterize these critical regulatory events. Researchers should begin by utilizing modification-specific antibodies that recognize particular PTMs such as phosphorylation, ubiquitination, or methylation on specific RPS17 residues; while commercial availability of such antibodies may be limited, custom antibody development against predicted or known modification sites represents a viable strategy . Two-dimensional gel electrophoresis followed by Western blotting with RPS17 antibodies enables separation of different PTM states based on changes in isoelectric point and molecular weight, providing a comprehensive profile of modification states under different cellular conditions . Immunoprecipitation with standard RPS17 antibodies followed by Western blotting with modification-specific antibodies (such as anti-phosphotyrosine, anti-ubiquitin, or anti-methylated lysine antibodies) represents another effective approach for identifying specific modifications on the immunoprecipitated protein . Mass spectrometry analysis of immunoprecipitated RPS17 offers unbiased identification of multiple PTMs simultaneously, revealing modification sites that may lack specific antibodies and providing quantitative information about modification stoichiometry . Proximity ligation assays combining RPS17 antibodies with modification-specific antibodies enable visualization of modified protein subpopulations within intact cells with subcellular resolution, revealing spatial regulation of RPS17 modifications . For functional studies, comparing PTM profiles across different physiological states (cell cycle phases, stress conditions, differentiation stages) helps establish connections between specific modifications and biological processes . Finally, combining these approaches with inhibitors of specific modifying enzymes (kinases, phosphatases, ubiquitin ligases) allows researchers to manipulate modification states and assess functional consequences on ribosome assembly, localization, and translation activity .

What are the current limitations in RPS17 antibody research and future directions?

Despite significant advances in RPS17 antibody applications, several limitations persist in current research methodologies while emerging technologies offer promising future directions. A primary limitation involves the relative scarcity of isoform-specific antibodies capable of distinguishing between RPS17 variants or paralogs, which constrains researchers' ability to investigate potential functional differences between these closely related proteins . The availability of modification-specific antibodies recognizing phosphorylated, ubiquitinated, or otherwise modified forms of RPS17 remains limited, hindering comprehensive characterization of its post-translational regulation in different cellular contexts . Current antibodies often lack sufficient sensitivity for detecting low levels of RPS17 in certain tissues or subcellular compartments, potentially obscuring important biological insights in systems with restricted expression . Future directions show considerable promise, with the development of recombinant antibody fragments (such as nanobodies) against RPS17 potentially offering superior penetration into dense structures like polysomes or nucleoli compared to conventional antibodies . Super-resolution microscopy combined with highly specific RPS17 antibodies will enable unprecedented visualization of ribosome assembly and localization at the nanoscale level, revealing spatial organization previously inaccessible to conventional microscopy . Multiplexed antibody-based imaging approaches will allow simultaneous detection of RPS17 alongside numerous other proteins, providing comprehensive spatial proteomics data on ribosome composition and interaction networks . Antibody-based proximity labeling techniques (such as TurboID or APEX2 fusions) coupled with mass spectrometry promise to reveal the dynamic RPS17 interactome in living cells with temporal resolution, capturing even transient interactions during ribosome assembly and function . Finally, improved antibody validation standards across the field will enhance reproducibility and reliability of RPS17 research, with initiatives promoting comprehensive characterization of antibody specificity across multiple applications and experimental systems .